|
IQVIA™ Real-World Insights Bibliography
| English demographics and cost of HIV-associated comorbidities in individuals over the age of 35: an investigation using the Hospital Episode Statistics (HES) database |
| Author(s): Wild L, Smith A, Sathia L, Davies S, Fernandez DP, Lawrence D. |
| Affiliations(s): 1Gilead Sciences, London, UK, 2IQVIA, London, UK |
Publication(s): HIV MEDICINE 2018 Apr 1 (Vol. 19, pp. S76-S77).
|
| Document Type(s): Abstract, Poster, |
| Countries: England, |
| Click here for the abstract |
C:
Y: |
HIV AIDS,
2022 |
|
L:
A: |
English
Cost consequence, Cost of illness, Database Study, Population Based Study, |
|
 |
| |
| |
| THE COST OF STIGMA ASSOCIATED WITH HIV- A COST-CONSEQUENCE ANALYSIS TO EVALUATE HIV TESTING AND PREVENTION INTERVENTIONS IN KSA |
| Author(s): Filemban S1, Elrashied S1, Assiri A1, Hakawi A1, Snehanshu S2, Mansour E3, Vemer P4, Awad N5 |
| Affiliations(s): 1Ministry of Health, Riyadh, Saudi Arabia,
2Gilead Sciences Middle East, Dubai Health Care City, United Arab Emirates, 3Gilead, Dubai, United Arab Emirates,
4Groningen University, Groningen, Netherlands,
5IQVIA, Dubai, United Arab Emirates |
Publication(s): 2019-11, ISPOR Europe 2019, Copenhagen, Denmark
|
| Document Type(s): Poster, |
| Countries: Saudi Arabia, |
| Click here for the abstract |
C:
Y: |
HIV AIDS,
2019 |
|
L:
A: |
English
Predictive analytics, Quality of life, |
|
|
| |
| |
| Economic Burden of HIV Antiretroviral Therapy Adverse Events in the United States. |
| Author(s): Dekoven M, Makin C, Slaff S, Marcus M, Maiese EM.
|
| Affiliations(s): IMS Health, Fairfax, VA, USA.
Yoh Services LLC, Philadelphia, PA, USA.
Merck Sharp & Dohme Corp, Whitehouse Station, NJ, USA emaiese@gmail.com |
Publication(s): J Int Assoc Provid AIDS Care. 2016 Jan-Feb;15(1):66-76
|
| Document Type(s): Article, |
| Countries: USA, |
| Click here for the abstract |
C:
Y: |
HIV AIDS,
2016 |
|
L:
A: |
English
Retrospective database analysis, |
|
|
| |
| |
| Cost effectiveness of darunavir/ritonavir 600/100 mg bid in treatment-experienced, lopinavir-naive, protease inhibitor-resistant, HIV-infected adults in Belgium, Italy, Sweden and the UK. |
| Author(s): Moeremans K1, Hemmett L2, Hjelmgren J3, Allegri G4, Smets E5 |
| Affiliations(s): 1 IMS Health, Brussels, Belgium 2 Tibotec, Buckinghamshire, UK 3 Janssen-Cilag AB, Stockholm, Sweden 4 Janssen-Cilag SpA, Cologno Monzese, Italy 5 Johnson & Johnson Pharmaceutical Services LLC, Mechelen, Belgium |
Publication(s): Pharmacoeconomics, 2010, 28 (Suppl 1): 147-167
|
| Document Type(s): Article, |
| Countries: Belgium, Italy, Nordic, Sweden, UK, |
C:
Y: |
HIV AIDS,
2010 |
|
L:
A: |
English
Cost effectiveness, |
|
|
| |
| |
| Cost-effectiveness of etravirine in Sweden in treatment-experienced HIV-1-infected adults with evidence of NNRTI resistance and ? 3 PI mutations. |
| Author(s): Moeremans K1, Hjelmgren J2, Martin S3 |
| Affiliations(s): 1 IMS Health, Brussels, Belgium 2 Janssen-Cilag, Birkeöd, Denmark 3 J&J, Mechelen, Belgium |
Publication(s): 12th European Aids Conference, 2009, November 11-14, Cologne, Germany
ISPOR 12th Annual European Congress, 2009, October 24-27, Paris, France
|
| Document Type(s): Poster, |
| Countries: Nordic, Sweden, |
C:
Y: |
HIV AIDS,
2009 |
|
L:
A: |
English
Cost utility, |
|
|
| |
| |
| Cost effectiveness of darunavir/ritonavir 600/100mg BID in treatment-experienced, LPV/R-naïve, PI-resistent, HIV-infected adults in the United Kingdom, Belgium, Italy and Sweden. |
| Author(s): Moeremans K, Hemmett L, Hjelmgren J, Allegri G, Smets E |
| Affiliations(s): |
Publication(s): ISPOR 11th Annual International Meeting, 2008, November 8-11, Athens, Greece
|
| Document Type(s): Oral presentation, |
| Countries: Belgium, Italy, Sweden, UK, |
C:
Y: |
HIV AIDS,
2008 |
|
L:
A: |
English
Cost effectiveness, |
|
|
| |
| |
| Cost-Effectiveness Analysis of Enfuvirtide (ENF) Added to an Optimized Therapy vs an Optimized Therapy Alone in Patients With HIV/AIDS. |
| Author(s): Badia X, Lizan L, Magaz S, Alvarez C, Green J, Serrano D. |
| Affiliations(s): |
Publication(s): HIV Clinical Trials 2007;8(4):235-45
|
| Document Type(s): Manuscript in preparation, |
| Countries: Spain, |
| Click here for the abstract |
C:
Y: |
HIV AIDS,
2007 |
|
L:
A: |
English
Cost effectiveness, |
|
|
| |
| |
| Experienced HIV/AIDS patients in different European healthcare settings |
| Author(s): Moeremans Karen, Annemans Lieven,; Smets Erik, Wyffels Veronique, Lothgren Mickael , Allegri Gabriele |
| Affiliations(s): |
Publication(s): ISPOR 2007 10th Annual European Congress
|
| Document Type(s): |
| Countries: Europe, |
C:
Y: |
HIV AIDS,
2007 |
|
L:
A: |
English
|
|
|
| |
| |
| Cost of care for HIV/AIDS in Belgium according to disease stage. |
| Author(s): Caekelbergh K1, Moeremans K1, Annemans L2, De Roo A3, Clumeck N4, Van Wijngaerden E5, Vandercam B6, Moutschen M7, Smets E8 |
| Affiliations(s): 1 IMS Health, Brussels, Belgium 2 Ghent University, Ghent, Belgium 3 Institute for Tropical Medicine, Antwerp, Belgium 4 St. Pierre University Hospital, Brussels, Belgium 5 University Hospital Leuven, Belgium 6 University Hospital St. Luc, Brussels, Belgium 7 University Hospital Sart Tilman, Liège, Belgium 8 Johnson & Johnson Pharmaceutical Services, Mechelen, Belgium |
Publication(s): 11th European AIDS Conference (EACS), 2007, October 24-27, Madrid, Spain
|
| Document Type(s): Oral presentation, |
| Countries: Belgium, |
C:
Y: |
HIV AIDS,
2007 |
|
L:
A: |
English
Cost of illness, |
|
|
| |
| |
| Cost-effectiveness of DRV/r in highly treatment-experienced HIV/AIDS patients in different European healthcare settings. |
| Author(s): Moeremans K, Annemans L, Smets E, Wyffels V, Wilson B, Lothgren M, Allegri G |
| Affiliations(s): |
Publication(s): 11th European AIDS Conference (EACS), 2007, October 24-27, Madrid, Spain
|
| Document Type(s): Oral presentation, |
| Countries: Belgium, |
C:
Y: |
HIV AIDS,
2007 |
|
L:
A: |
English
Cost effectiveness, |
|
|
| |
| |
 1 of 2 
|
|
